All In Biotech

Drug Trial Radar · NCT07888569

Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)

A Single-sequence, Open-label, Three-period, Crossover Study to Evaluate the Effect of Rabeprazole, a Proton Pump Inhibitor, on Pharmacokinetics of DZD8586 (Birelentinib) in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Nov 23, 2026

Study completion Nov 23, 2026

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy participants.

Conditions

  • Healthy

Interventions

  • DZD8586Drug

    DZD8586 administered by mouth as a single dose in Period 1 (without food), Period 2 (with rabeprazole with food) and Period 3 (with rabeprazole without food).

  • RabeprazoleDrug

    Rabeprazole administered by mouth once a day for 7 days in Period 2 and 7 days in Period 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-inf of DZD8586Time frame: Up to 120 hours post-dose
  2. AUC0-t of DZD8586Time frame: Up to 120 hours post-dose
  3. Cmax of DZD8586Time frame: Up to 120 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.